Effects of voriconazole in patients with invasive fungal infections having different CYP2C19 genotype.

Trial Profile

Effects of voriconazole in patients with invasive fungal infections having different CYP2C19 genotype.

Completed
Phase of Trial: Phase IV

Latest Information Update: 14 Jan 2015

At a glance

  • Drugs Voriconazole (Primary) ; Voriconazole (Primary)
  • Indications Mycoses
  • Focus Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 14 Jan 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top